Lajos Pusztai, MD, PhD: Update on Triplet Regimen for High-Risk HER2-Negative Breast Cancer

Posted: Monday, May 4, 2020

Lajos Pusztai, MD, PhD, of Yale Cancer Center, discusses the I-SPY2 study, which investigated the combination of durvalumab, olaparib, and paclitaxel, and its therapeutic implications for patients with high-risk HER2-negative stage II/III breast cancer or triple-negative disease.